Powerful partnerships help drive our research for the greater good
The Institute for Glycomics has a broad portfolio of technologies and services available to industry, investors and academic organisations. It has a management framework and expert personnel in place to meet industry demands and has successfully co-developed products using its translational capability and specialised facilities from concept to market.
Technologies available
For Industry
The Institute for Glycomics has a portfolio of discovery to Phase 1 technologies and novel technology platforms available for licensing and co-development. It has successfully co-developed several of its drug and vaccine assets from preclinical stage to Phase 2 human clinical trials through industry partnerships.
For investors
The Institute has a suite of technology packages available for immediate investment. The Institute is experienced in negotiating and managing a range of investment types.
Success stories
World’s largest commercial glycan array launched
The Institute for Glycomics has partnered with Dextra Laboratories to launch the world’s largest commercial glycan array and bioanalytical service offering.
Ross River virus battle breakthrough
Research conducted by Griffith and Paradigm Biopharmaceuticals has uncovered a potential new treatment in the battle against alphavirus infections.
Strep A vaccine partnership raises hope
The Institute for Glycomics has partnered with Dextra Laboratories to launch the world’s largest commercial glycan array and bioanalytical service offering.